Maxime Verhoeven

99 TCZ vs. TCZ+MTX; prevention of radiographic progression in RA Supplementary Figure S2 Relative chance of preventing radiographic progression established RA.* Number of patients in low level baseline joint damage subgroup; 96 in TCZ vs. 110 in TCZ+MTX, number of patients in high level baseline joint damage subgroup; 105 in TCZ vs. 106 in TCZ+MTX. Number of patients in low level baseline disease duration subgroup; 103 in TCZ vs. 105 in TCZ+MTX, number of patients in high level baseline disease duration subgroup; 99 in TCZ vs. 110 in TCZ+MTX. Number of patients in low level baseline DAS28 subgroup; 103 in TCZ vs. 104 in TCZ+MTX, number of patients in high level baseline DAS28 subgroup; 99 in TCZ vs. 111 in TCZ+MTX. *Relative chances (95%CI) are based on stratified analyses, controlling for age, gender and DAS28 at baseline. A RR above 1 is associated with less radiographic progression for TCZ. Low/high levels of baseline joint damage (SvdH score ≤28.5/>28.5), disease duration (≤5.46 years/>5.46 years) or disease activity (DAS28 ≤6.37/>6.37) were based on their respective median values in the data. RA= rheumatoid arthritis; SvdH= Sharp van der Heijde; TCZ= tocilizumab; MTX= methotrexate; RR= relative chance; % Ref= proportion of patients with no progression (i.e., based on raw data) in the reference group, i.e., TCZ+ MTX group. 5